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Summary 
Human leukocyte antigen and killer immunoglobulin-like receptor alleles were assessed for 
association with cervical neoplasia. Our findings suggest HLA-C1 group alleles protect against HPV16-
related cervical neoplasia, mainly through a KIR-mediated mechanism. 
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ABSTRACT 
 
Background: Cervical cancer is the fourth most common cancer in women, and we recently reported 
human leukocyte antigen (HLA) alleles showing strong associations with cervical neoplasia risk and 
protection. HLA ligands are recognised by killer immunoglobulin-like receptors (KIRs) expressed on a 
range of immune cell subsets, governing their proinflammatory activity. We hypothesized that the 
inheritance of particular HLA-KIR combinations would increase cervical neoplasia risk.  
Methods: Here, we used HLA and KIR dosages imputed from SNP genotype data from 2,143 cervical 
neoplasia cases and 13,858 healthy controls of European decent.  
Results: Four novel HLA alleles were identified in association with cervical neoplasia: HLA-
DRB3*9901 (OR=1.24, P=2.49×10−9), HLA-DRB5*0101 (OR=1.29, P=2.26×10−8), HLA-DRB5*9901 
(OR=0.77, P=1.90×10−9) and HLA-DRB3*0301 (OR=0.63, P=4.06×10−5), due to their linkage 
disequilibrium with known cervical neoplasia-associated HLA-DRB1 alleles. We also found 
homozygosity of HLA-C1 group alleles is a protective factor for HPV16-related cervical neoplasia 
(C1/C1, OR=0.79, P=0.005). This protective association was restricted to carriers of either KIR2DL2 
(OR=0.67, P=0.00045) or KIR2DS2 (OR=0.69, P=0.0006).  
Conclusions: Our findings suggest that HLA-C1 group alleles play a role in protecting against HPV16-
related cervical neoplasia, mainly through a KIR-mediated mechanism.  
 
Keywords: Cervical neoplasia; human leukocyte antigens (HLA); killer immunoglobulin-like receptors 
(KIRs); HPV16-related cervical neoplasia. 
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BACKGROUND  
Cervical cancer is the fourth most common cancer in women, with over 500,000 new cases 
presenting world-wide in 2012, and accounting for 7.5% of female cancer deaths [1]. Its impact is 
particularly high in young women as the second commonest cancer affecting women aged 20-39 
years [2]. Cervical cancer results from chronic infection with human papillomavirus (HPV), with the 
HPV genome detected in nearly all cervical cancers. Of the different HPV types, HPV16 and –18 are 
the most frequently involved, and together account for approximately 70% of cervical cancers 
world-wide [3]. Whilst infection with HPV is essentially universal, most cervical HPV infections are 
cleared by the immune system [4, 5], and only ~1% of women with cervical HPV infection develop 
cervical cancer [6]. 
 
Genetic factors strongly influence persistence of HPV infection and risk of cervical cancer. HPV 
persistence is associated with the monogenic disorders epidermodysplasia verruciformis and WHIM 
syndrome, from mutations in EVER1/2 and CXCR4, respectively [7, 8]. The only robust common 
variant genetic associations with cervical cancer are with genes of the major histocompatibility 
complex (MHC), in particular human leukocyte antigens (HLA). We demonstrated that haplotypes 
HLA-DRB1*1501/HLA-DQB1*0602/HLA-DQA1*0102 and HLA-DQA1*0301/HLA-DRB1*0401 increase 
the risk of HPV-associated cervical neoplasia, and that the allele HLA-B*15 and haplotype HLA-
DRB1*1301/HLA-DQB1*0603 are protective. Of note, HLA-DRB1*1301/HLA-DQA1*0103/HLA-
DQB1*0603 is associated with protection from oral and pharyngeal cancer, particularly HPV-positive 
cases [9]. We showed that the HLA risks of cervical neoplasia were determined by amino acids at 
positions 13 and 71 in pocket 4 of HLA-DRB1 and position 156 in HLA-B [10]. Common genetic 
variant contribution to cervical neoplasia susceptibility is substantial (36%) [10], although a large 
component of the heritability has yet to be elucidated.  
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HLA proteins are critical for antigen presentation to effector cells of the adaptive immune system 
[11]. HLA Class I complexes are expressed on all nucleated cells and present endogenous, 
intracellular-derived antigens, as well as pathogen-derived peptides (as with viral infection), with 
residue length of 8-10 amino acids. These are recognized by CD8+ T-cells that can engage foreign 
peptides through their T-cell receptor. Conversely, natural killer (NK) cells, a component of the 
innate immune system, are able to respond to downregulated surface HLA, a consequence of the 
immune evasion strategy of some viruses to avoid CD8+ T-cell recognition. Once activated, these 
lymphocytes can kill the antigen-presenting cell via release of cytotoxic granules. HLA Class II 
complexes typically present extracellular-derived antigens, such as bacterial pathogens. After 
endocytosis, these proteins are processed and presented on the cell surface bound to MHC Class II, 
to initiate an immune response from CD4+ cells.  
 
Interaction between HLA, viral epitopes, and killer-immunoglobulin-like receptors (KIR) expressed on 
NK cells lead either to activation or inhibition of NK cell cytotoxic activity. KIRs are expressed on all 
NK cells, and a minority of T-cells (including some CD4+, CD8+ and cells). Seventeen KIR genes have 
been identified, encoded within the leukocyte receptor complex (LRC) on chromosome 19q13.4, all 
of which share significant homology (85-99% DNA sequence similarity) [12, 13]. They are encoded in 
variable gene content haplotypes with activating and inhibitory counterparts. Different inhibitory 
and activating KIRs demonstrate specificity for different HLA subgroups, providing fine-tuning of NK 
and KIR-bearing T-cell responses [14]. 
 
Variability at the KIR locus includes allelic, gene combination (haplotypic), and expression level 
differences, the latter under significant epigenetic control [15]. KIR genes are inherited in haplotypes 
of vastly diverse content, ranging from 4-14 receptor-encoding loci, with over 50 distinct haplotypes 
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based on gene content alone [13, 16]; with ~700 allelic variants have been reported [16, 17]. Group 
1 HLA-C (HLA-C1) allotypes have an asparagine at residue 80, and are ligands for the inhibitory 
receptors, KIR2DL2 and KIR2DL3, which segregate as alleles of a single locus, and KIR2DS2 [18]. The 
remaining HLA-C allotypes (group 2, HLA-C2) have a lysine at position 80, and are ligands for KIR2DL1 
(an inhibitory receptor) and KIR2DS1 (the homologous activating receptor). HLA-B Bw4 allotypes 
serve as ligands for KIR3DL1 and KIR3DS1 (Fig. 1). 
 
The immunological mechanisms involved in clearance of HPV are poorly understood. NK cells are 
crucial for clearing viral infection and for anti-tumour immunity, and are thought to be important in 
HPV control [19]. Regulation of NK cell responses depend on KIR genotype, HLA genotype, 
heterozygosity versus homozygosity for each of these, interaction of HLA and KIR, and changes in KIR 
and HLA expression. The development of imputation-based methods for HLA typing, and more 
recently for KIR typing, has enabled the use of SNP-typed datasets to investigate genetic associations 
with these loci in large cohorts. Here, HLA and KIR gene imputation and association tests were 
performed using genotype data from 2,143 cervical neoplasia cases and 13,858 healthy controls of 
European descent, to test whether HLA-KIR combinations are associated with cervical neoplasia risk. 
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Phenotypic information, including cervical histology and HPV genotype, appears in Supplementary 
Table S1. As described in Leo et al. [10], all cases needed to have CIN2/3 (if CIN2, age over 30 to limit 
analysis to women who failed to clear HPV) or cervical cancer (HPV type and histology not always 
known). HPV DNA types from tumor tissues were categorized into six groups: a) HPV16-positive (but 
not HPV18); b) HPV18-positive (but not HPV16); c) neither HPV16 nor HPV18; d) both HPV16 and 
HPV18; e) negative for any HPV (noting that usually samples are only tested for HPV16 and HPV18); 
and f) those not tested for HPV genotype [10].  
 
Genotyping  
Case samples were SNP microarray genotyped in-house. 791 cases were genotyped using Illumina 
OmniExpress BeadChips (‘Omni’) and 1,352 cases using Illumina Human660-Quad BeadChips 
(‘660Q’). Controls were genotyped using Illumina Immunochip BeadChips (‘Ichip’; Fig. 2). Bead 
intensity data were processed and normalized for each sample, and genotypes called within 
participating studies using GenomeStudio, and verified manually and corrected where necessary. 
Standard quality control measures were performed [10], with particular care taken in comparison of 
the performance of different chip types. 
  
HLA imputation 
HLA alleles were inferred using HLA*IMP:03 
(http://www.biorxiv.org/content/early/2016/12/09/091009). Individuals with posterior probability 
of HLA alleles < 0.6 were excluded from downstream association testing (Supplementary Fig. S1). 
HLA groups (C1, C2, Bw4, Bw6) were inferred from known allele classifications. HLA amino acids 
were inferred by SNP2HLA [20], using a reference panel from the Type 1 Diabetes Genetics 
Consortium (N=5,225). Amino acids imputed by SNP2HLA with r2 <0.5 were excluded, and samples 
where the allele dosage at any HLA type exceeded 2.5 were removed. 
METHODS AND MATERIALS 
Study Population 
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KIR imputation 
KIR genes and haplotypes were imputed with KIR*IMP [21] using SNP genotypes across the KIR 
locus. This requires certain informative ‘key’ SNPs for accurate imputation, which vary according to 
the SNP chip used (see Supplementary Table S2). To avoid imputation bias caused by different 
numbers of key SNPs genotyped by the Omni and 660-Quad BeadChips, the two groups of cases 
were imputed separately, with a separate comparator group for each obtained by randomly dividing 
the control group into two: Ichip control group 1 (Ichip1, n=6,703) and group 2 (Ichip2, n=6,725; Fig 
2). Imputed data for KIR and HLA loci were compared between the two control groups. There were 
no significant differences between the two control groups for 271 KIR SNPs (noting that most of 
these were only available on Ichip, not on chips used for case genotyping, hence the smaller number 
available for case-control analyses). Of 256 HLA alleles, 10 alleles (3.9%) were significantly different 
(P<0.05) between the two control groups. Most (8/10) were rare (≤0.05); the remaining two had 
frequency 0.08. None of these SNPs were significant in subsequent analyses. The 77 key SNPs for 
Omni cases and Ichip1, and the 66 key SNPs for 660Quad cases and Ichip2, were re-clustered 
manually (converting array intensity data for each allele of the SNP concerned to genotype calls) 
before imputation to improve genotyping accuracy (Supplementary Table S3). Individuals with 
posterior probability of accurate KIR imputation for each KIR allele <0.6 were excluded in the 
downstream association testing. 
  
Statistical Methods 
Population stratification was assessed via principal component analysis of genome-wide genotypes 
using Shellfish (http://www.stats.ox.ac.uk/~davison/software/shellfish/shellfish.php). Association 
analyses were performed using custom R scripts. Three models were applied to test HLA-C1, HLA-C2, 
HLA-Bw4, HLA-Bw6 and HLA alleles, and their combination with KIR genes: a) dosage model, treating 
genotypes as 0, 1, or 2 copies; b) dominant model, treating 1 or 2 copy genotypes as present, 0 as 
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absent; and c) recessive model to study the difference of homozygotes and heterozygotes of HLA-B 
and HLA-C, treating 2 copy genotypes as present, 0 or 1 copy as absent. Meta-analysis of 
combination between Omni-Ichip1 and 660Q-Ichip2 was performed using METAL software 
(http://csg.sph.umich.edu/abecasis/metal/). For tests over all HLA alleles, the multiple testing 
correction methodology was employed [22, 23], using a correlation matrix derived from SNP2HLA 
imputation with all 1027 HLA alleles and amino acids. This analysis estimated 206 independent loci, 
implying a Bonferroni correction to P=2.4×10−4 for a type I error rate of 5%. For the HLA-KIR 
interaction using 12 KIR alleles we applied the most conservative Bonferroni correction (P= 
(0.05/(206x12) = 2.0×10−5 for statistical significance). 
 
RESULTS 
Quality Control 
2,143 cases and 13,428 controls passed quality control. Amongst cases, 736 were squamous cell 
carcinoma, 542 adenocarcinoma, and 865 with histology unspecified. Four principal components 
were used as covariates to control for population stratification, calculated using 11,980 common 
SNPs shared by the Illumina OmniExpress, 660-Quad and Immunochip SNP microarrays. To assess 
population stratification, we used a subset of 333 “null” SNPs outside the MHC region included on 
each chip type, and avoiding SNPs included on Immunochip, because of their potential 
immunogenetic significance, associated with reading and learning disability, schizophrenia and 
psychosis.  From this, the genomic inflation factor overall was calculated as 1.018 (Supplementary 
Fig. S2). No divergences were observed between cases and controls, or different genotype platforms 
(Supplementary Fig. S3). All HLA loci were imputed above 95% accuracy (Supplementary Table S4), 
and all KIR loci imputed above 80% accuracy (Supplementary Table S3). 
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MHC Findings 
HLA Association Analysis 
Consistent with our recent study [10], we found increased and decreased risk of cervical neoplasia 
associated with HLA haplotypes (Supplementary Table S5), and determined these associations are 
carried by amino acids at positions 13 and 71 in pocket 4 of HLA-DRB1, and position 156 in HLA-B. 
Using these in-depth imputation methods across HLA and KIR loci, we detected further novel 
associations from HLA-DRB3 and –DRB5.  
 
Novel risk associations with cervical neoplasia were identified with HLA-DRB3*9901 (OR=1.24, 
P=2.49×10−9; Table 1) and HLA-DRB5*0101 (OR=1.29, P=2.26×10−8). Although HLA-DRB3*9901 is not 
in linkage disequilibrium with any individual cervical neoplasia HLA risk allele (P<0.05), adjusting for 
the association with HLA-DRB1 amino acid positions 37, 71 and 96 attenuates the association with 
HLA-DRB3*9901 (P>0.01). HLA-DRB5*0101 is in positive linkage disequilibrium with the HLA Class II 
risk allele, HLA-DRB1*1501 (r2=0.99), and protective allele, HLA-DRB5*9901 (r2=0.93; Table 1 and Fig. 
3). No residual association HLA-DRB5*0101 was observed after controlling for the association of 
HLA-DRB1*1501, HLA-DRB5*9901, or HLA-DRB1 amino acid positions 13 and 71 (P<0.01).  
 
Novel inverse associations with cervical neoplasia were observed with HLA-DRB5*9901 (OR=0.77, 
P=1.90×10−9) and HLA-DRB3*0301 (OR=0.63, P=4.06×10−5). HLA-DRB5*9901 is in positive linkage 
disequilibrium with the HLA Class II risk alleles, HLA-DRB1*1501 (r2=0.93) and HLA-DRB5*0101 
(r2=0.93; Table 1 and Fig. 3). No residual association at these two HLA loci was observed after 
controlling for the association of HLA-DRB1 amino acid 71 (P<0.01; Table 1). 
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HLA alleles were associated with disease when assessing HPV genotype, without regard to histologic 
classification. Comparing HPV16-related cases (N=667) with all controls (N=13,428), risk associations 
were observed with HLA-DRB3*9901 (OR=1.43, P=1.27×10−8; Supplementary Table S6). Controlling 
for the association with HLA-DRB1 amino acid positions 13 and 37 controls for the association of 
HLA-DRB3*9901 (P>0.01). For HPV18-related cervical neoplasia (cases=166), the strongest 
associated HLA allele was HLA-DPA1*0103 (OR=1.89, P=0.00039; Supplementary Table S7). 
Considering histopathology, reduced risk was seen in HLA-DRB5*9901 with squamous cell carcinoma 
(OR=0.72, P=6.57×10−5). No residual association was observed after controlling for the association of 
HLA-DRB1 amino acids 13, 17 and 96 (P<0.01). Increased risk was seen in HLA-DRB3*9901 with 
adenocarcinoma (OR=1.31, P=7.38×10−5; Supplementary Table S8). No residual association was 
observed after controlling for the association of HLA-DRB1 amino acids 13, 71 and 96 (P<0.01). 
 
HLA-Bw4/Bw6 and HLA-Cw1/Cw2 Association Analysis 
Dominant and dosage models showed a nominal risk association of HLA-Bw4 in HPV16-related 
cervical neoplasia (OR=1.24, P=0.014 and OR=1.16, P=0.011, respectively; Table1 and Supplementary 
Table S9). The dosage model suggests that HLA-Bw4 has a weak inverse association with HPV18-
related cervical neoplasia (OR=0.78, P=0.04). No association was found between HLA-Bw4 or Bw6 
with cervical cancer overall, squamous cell carcinoma or adenocarcinoma.  
 
All three models suggested HLA-C1/2 alleles are associated with HPV16-related cervical neoplasia 
(Supplementary Table S10). HLA-C1 and HLA-C2 are mutually exclusive, meaning one can have two 
copies of either or one copy of each. Both HLA-C1 and HLA-C2 can interact with specific KIR and lead 
to inhibitory or activating signaling. To investigate the role of HLA-C1 or HLA-C2, and their 
combination with KIR, we employed a recessive model to distinguish HLA-C homozygotes and 
heterozygotes. The frequency of individuals with two copies of HLA-C1 alleles was lower in HPV16-
related cervical neoplasia cases (35.7%) than controls (41.3%) (P=0.005, OR=0.79; Table 2). The 
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frequency of two copies of HLA-C2 alleles did not differ between the groups. No association was 
found between HLA-C1 or HLA-C2 with cervical cancer overall, HPV18-related cervical cancer, 
squamous cell carcinoma or adenocarcinoma.  
 
KIR Findings 
KIR imputation concordance was explored by comparison of KIR haplotype frequencies between four 
datasets (Supplementary Fig. S4), comparison with published population prevalences 
(Supplementary Fig. S5), and control-control association test (group1 vs. group2, using the randomly 
divided Ichip dataset; Supplementary Table S11). For the control-control association test of 16 
imputed KIR loci, four (KIR2DS3, KIR2DL1, KIR2DP1 and KIR2DL5) were inconsistent due to the 
different key SNP numbers in each group, and were not analysed further. Prevalences of the other 
12 KIR genes were concordant between groups. No association was found between KIR genes with 
cervical cancer overall, or with HPV18-related cervical cancer. Weak protective association was seen 
with KIR2DL2 with HPV16-related cervical cancer (Pmeta=0.04, ORomni=0.87, OR660Q=0.83). 
 
KIR-HLA-Bw4/Bw6 and KIR-HLA-C1/2 combination 
No KIR-HLA-Bw4/Bw6 or KIR-HLA-C1/2 combination was associated with cervical neoplasia, HPV18-
related cervical neoplasia, squamous cell carcinoma or adenocarcinoma. HLA-Bw4 alleles were 
associated with increased risk of HPV16-associated cervical neoplasia, this association being 
restricted to KIR3DL1 carriers (Pmeta=0.0085; OR=1.22). No association was seen in individuals 
presenting with Bw6 HLA-B alleles. 
 
KIR2DL3 and KIR2DL2 bind HLA-C1 allotypes, with KIR2DL2 binding with greater affinity [18]. The 
protective association for HPV16-related cervical neoplasia of HLA-C1/C1 was restricted to 
individuals carrying KIR2DL2 (Pmeta=0.00045; OR=0.67), or KIR2DS2 (Pmeta=0.0006; OR=0.69), these 
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KIR alleles often being found together on KIR haplotypes. In our dataset, KIR2DL2 and KIR2DS2 are in 
near complete linkage disequilibrium (r2=0.99). KIR2DL2 and KIR2DL3 were not associated with 
cervical neoplasia in individuals who were lacking HLA-C1/C1. HLA-C2 can interact with either 
KIR2DS1 or KIR2DL1. No association with HPV16-related cervical neoplasia was seen in individuals 
with KIR2DS1 and HLA-C2. KIR2DL1 could not be investigated in this study due to the low KIR2DL1 
imputation accuracy. 
 
KIR and HLA allele combinations 
The strongest associations of any combination of KIR and HLA alleles with cervical neoplasia was 
HLA-B*5501 and KIR2DS2 (Pmeta=5.97×10
−5; ORomni=0.61, OR660Q=0.19) and HLA-B*5501 and KIR2DL2 
(Pmeta=0.00013, ORomni=0.6, OR660Q=0.2, Table 3 and Supplementary Fig. S6). HLA-B*5501 was not 
associated with cervical neoplasia independent of this interactive association with KIR genes. 
 
DISCUSSION 
Here, we report novel associations of combinations of HLA and KIR alleles with cervical neoplasia. 
We also extend our previous findings of protective and risk haplotypes associated with cervical 
neoplasia, demonstrating association of HLA-DRB3 and HLA-DRB5 alleles with the disease, and 
confirm that these are due to linkage disequilibrium with HLA-DRB1 amino acids [10]. In our 
previous GWAS, no significant association was noted at the LRC on chromosome 19q13, but many 
SNPs at this locus failed quality control because the complex genetic structure of the locus leads to 
reduced accuracy of genotype calling by automated algorithms. In the current study, careful manual 
checking of genotype calling was performed, KIR genotypes were imputed, and analysed in 
combination with HLA alleles. 
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We used imputation methods to infer HLA and KIR genotypes from SNP microarray data to perform 
one of the largest HLA-KIR association studies reported to date. By comparing our imputed KIR 
haplotype and KIR gene prevalences with published data generated using direct genotyping 
approaches, we confirmed that concordance between genotyped and imputed data is high. We 
further compared our imputation findings with direct HLA and KIR genotype data in 86 1000 
Genome study samples. The concordance for HLA genes in 2-digit and 4-digit resolution was 99.77% 
and 99.42%, respectively (data not shown). Whilst we were able to impute 16 KIR genes, the 
imputation of four genes was inconsistent between our two cohorts, and therefore not considered. 
Of the remaining twelve, two (KIR3DP1, KIR2DL4) are framework KIR genes present in all individuals, 
and thus association with disease cannot be calculated for these genes. For the remaining ten KIR 
genes, we did not find differences between cases and controls in isolation, but demonstrate 
suggestive associations in combination with specific HLA alleles.  
 
We identified three new HLA allelic associations with cervical neoplasia, HLA-DRB5*0101 and –
DRB3*9901 as risk factors, and HLA-DRB3*301 as a protective factor. HLA-DRB3, –DRB4 and –DRB5 
are paralogues of HLA-DRB1 with which they are in linkage disequilibrium, and their expression level 
is one fifth that of HLA-DRB1 (RefSeq, Jul 2008). Consistent with the strong linkage disequilibrium 
across this locus, the associations of the HLA-DRB3 and HLA-DRB5 alleles with cervical neoplasia in 
this study were due to linkage disequilibrium with HLA-DRB1 alleles and amino acid variants. 
 
Homozygosity of the HLA-C1 genotype group (C1/C1) overall was associated with protection from 
HPV16-related cervical neoplasia. This protective association was restricted to carriers of either 
KIR2DL2 or KIR2DS2, suggesting it operates through a KIR-mediated mechanism. A role for HLA-C1 
genotypes in cervical neoplasia is supported by previous studies, although the direction of 
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association has not been consistent, and studies have generally been small. A study of cervical 
cancer-affected parent-case trios showed that HLA-C1 was over-transmitted in women with invasive 
cervical cancer (P=0.04), particularly in the subgroup of women infected with HPV16 or –18 types 
(P=0.008) [24]. A study using unrelated cases and controls of European ancestry showed HLA-
C1/KIR2DL2 and HLA-C1/KIR2DL3 pairs were decreased in patients with HPV-positive cervical lesions, 
and increased in HPV high-risk infected patients, compared with HPV low-risk group [25]. Whilst 
these studies are not definitive, they suggest involvement of HLA-C1 group alleles in modulating the 
risk of cervical neoplasia, perhaps through their function as KIR ligands.  
 
Several small candidate gene studies of the KIR locus and cervical cancer have been performed. 
Consistent with our findings, a Western Australian cohort study of 147 cases demonstrated weak 
association of KIR2DL2 and KIR2DS2 with high-grade CIN (CIN2 and 3) overall (P=0.046 and P=0.049, 
respectively) [26]. A study of Eastern U.S. and Costa Rican individuals (196 cases, 330 controls) 
indicated KIR3DS1 increased, and HLA-C2 alleles reduced, the risk of cervical cancer [27]. Our data 
do not support these findings. Other studies from Sweden (65 cases) [28], Brazil (79 cases) [29] and 
Korea (132 cases) [30] have not reported positive associations, although their samples sizes were 
too small to identify anything other than essentially monogenic risk-associations. 
 
The strongest HLA-KIR combination association with cervical neoplasia observed in this study was 
between HLA-B*5501 and KIR2DL2/DS2 (Pmeta=5.97×10
−5), although this did not meet the 
conservative Bonferroni-corrected significance threshold of P=2.0×10−5 for HLA-KIR interactions. 
Whilst HLA-B*5501 frequency did not differ between cases (3.5%, 71/2,015) and controls (3.4%, 
426/12,458), suggestive associations of the combination of HLA-B*5501 and either KIR2DS2 or 
KIRSDL2 were observed. The signal was mainly contributed to by the 660Q-Ichip2 data. No 
imputation bias was found in KIR2DS2, KIR2DL2 and HLA-B*5501 between case-case and control-
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control tests, suggesting that this is not due to imputation artefact, but in the absence of clear 
replication, further studies are required to determine its significance. HLA-B55 has been reported to 
be associated with cervical neoplasia, but this has not been replicated in larger studies [31]. KIR2DS2 
and KIR2DL2 bind a range of HLA-C1 group allotypes, which include HLA-B46 and HLA-B73, but not 
HLA-B55. HLA-B55 is an HLA-Bw6 allele, a group that does not bind KIR. It is possible that the 
association we observed here is due to linkage disequilibrium with other HLA types, or it may be a 
non-informative suggestive association, particularly given that it was only found in comparison with 
one of the two imputation sets. 
 
CONCLUSIONS 
Cervical neoplasia may be associated with HLA-C1 group alleles that interact with KIR in controlling 
NK cell activation. Further HLA associations were demonstrated and shown to be driven by linkage 
disequilibrium with known amino acid components of HLA-DRB1 allelic associations of disease, 
further supporting that these variants are key to HLA-associations of cervical neoplasia. No definitive 
KIR associations were noted with cervical neoplasia, although we only examined KIR gene carriage 
and not allelic variation within KIR genes, for which larger and more densely sequenced reference 
datasets for imputation will be required. Further studies of KIR allelic variation are warranted, 
particularly given the role of KIR-bearing cells in immunity to viral infection, and the suggestive 
association of HLA-C1 variants observed with disease. 
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Table 1. Analysis of novel cervical neoplasia associated HLA alleles, conditioned on HLA alleles and HLA 
amino acids.  
 HLA Alleles DRB3*9901 DRB5*0101 DRB5*9901 DRB3*0301 
 
Unconditioned P-values 2.49×10−9 2.26 ×10−8 1.90×10−8 4.06×10−6 
Odds ratio 1.24 1.29 0.77 0.63 
Conditioned 
P-values 
DRB3*9901 NA 4.19×10−5 3.66×10−5 0.001033 
DRB5*0101 3.07×10−5 NA 0.45 4.43×10−5 
DRB5*9901 3.21×10−5 0.66 NA 4.50×10−5 
DRB3*0301 1.24×10−6 8.7 ×10−8 7.41×10−8 NA 
DRB1*1501 1.99×10−5 0.21 0.37 5.28×10−5 
B*0702 9.64×10−6 0.0040 0.0040 6.49×10−5 
DQB1*0602 6.94×10−6 0.0059 0.0043 1.81×10−5 
DRB1*1302 3.18×10−6 4.33×10−8 4.45×10−8 0.14 
DRB1_11 0.0018 0.055 0.056 0.0063 
DRB1_13 4.73×10−6 0.01 0.0096 0.013 
DRB1_37 0.11 0.01 0.0092 0.0063 
DRB1_71 0.013 0.04 0.037 0.84 
DRB1_96 0.49 0.00058 0.0006 0.001 
DRB1_13 & 71 2.26×10−5 0.37 0.94 0.54 
DRB1_71 & 96 0.84 0.046 0.086 0.7 
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Table 2. KIR-HLA-Bw4/ Bw6 and KIR-HLA-C1/C2 type combinations associated with HPV16-related 
cervical neoplasia.  
Genetic factor Frequency HPV16+ 
cases 
Frequency controls OR 95%CI P-values 
HLA-C1/C1 
232/649 (35.7%) 5434/13148 (41.3%) 
0.79 0.67-0.93 
0.005 
HLA-C1/C2 326/649 (50.2%) 6054/13148 (46%) 1.18 1.01-1.38 0.039 
HLA-C2/C2 91/649 (14.0%) 1660/13148 (12.6%) 1.13 0.90-1.42 0.29 
      
2DL2 295/633 (46.6%) 6658/13073 (50.9%) 0.84 0.72-0.99 0.04 
2DL3 596/647 (92.1%) 11942/13188 (90.6%) 1.22 0.91-1.63 0.25 
2DS2 310/648 (47.8%) 6751/13167 (51.3%) 0.87 0.74-1.02 0.08 
      
2DL2-C1/C1 96/624 (15.4%) 2754/12932 (21.3%) 
0.67 0.54-0.84 
0.00045 
C1/C1 in 2DL2+ 96/291 (33.0%) 2754/6587 (41.8%) 0.69 0.51-0.88 0.0029 
C1/C1 in 2DL2- 131/333 (39.3%) 2599/6345 (41.0%) 0.93 0.75-1.17 0.56 
      
2DL3-C1/C1 216/638 (33.9%) 4890/13044 (37.5%) 0.85 0.72-1.01 0.09 
2DL2-C1/C2 158/624 (25.3%) 3027/12932 (23.4%) 1.11 0.92-1.33 0.29 
2DL3-C1/C2 291/638 (45.6%) 5432/13044 (41.6%) 1.18 1.00-1.38 0.053 
      
2DS2-C1/C1 101/639 (15.8%) 2791/13023 (21.4%) 0.69 0.55-0.85 0.0006 
C1/C1 in 2DS2+ 101/306 (33.0%) 2791/6677 (41.8%) 0.68 0.54-0.87 0.0024 
C1/C1 in 2DS2- 131/333 (39.3%) 2599/6346 (41.0%) 0.93 0.75-1.17 0.56 
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2DS2-C1/C2 165/639 (25.8%) 3068/13023 (23.6%) 1.13 0.94-1.35 0.23 
2DS1-C2/C2 22/652 (3.4%) 573/13199 (4.3%) 0.77 0.50-1.19 0.15 
      
HLA-Bw4 406/623 (65.2%) 7459/12375 (60.3%) 1.24 1.04-1.46 0.014 
3DL1-HLA-Bw4 388/623 (62.3%) 7111/12375 (57.5%) 1.22 1.03-1.44 0.0085 
HLA-Bw4 in 3DL1+ 388/601 (64.5%) 7111/11805 (60.2%) 1.20 1.02-1.43 0.034 
HLA-Bw4 in 3DL1- 18/22 (81.8%) 348/570 (61.1%) 2.8 0.96-8.6 0.059 
      
3DS1+HLA-Bw4 156/623 (25.0%) 2773/12371 (22.4%) 1.16 0.96-1.39 0.09 
 
Frequencies of HLA-B, HLA-C and KIR-HLA-B, C combinations among individuals with HPV16 infected 
cervical cancer cases and healthy controls are shown. HLA-C1C1 indicates two group 1 HLA-C alleles, 
HLA-C2C2 indicates two group 2 HLA-C alleles, and HLA-C1C2 indicates one of each. HLA-Bw4 
indicates one or two group Bw4 alleles. P-values were calculated by using R code glm model with 
principle components 1-4, combination P-values were calculated from meta-analysis between Omni-
Ichip1 and 660Q-Ichip2 datasets; a positive odds ratio indicates a protective association with HPV16 
infection. 
CI: 95% Confidence Interval; HLA-C1: HLA-C01, 03, 07, 08, 12, 13, 14, 16 and HLA-B4601, 7301; HLA-
C2: HLA-C02, 04, 05, 06, 15, 17, 18; HLA-Bw4: HLA-B05, 5102, 5103, 13, 17, 27, 37, 38, 44, 47, 49, 51, 
52, 53, 57, 58, 59, 63, 77; OR: Odds Ratio. 
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Table 3. KIR-HLA combinations are associated with cervical neoplasia.  
 
Combination  OR Sample size FRQ of HLA FRQ of KIR KIR+HLA+ KIR-HLA- KIR+HLA- KIR-HLA+ 
HLA alleles KIR genes P-values 
Omni-
Ichip1 
660Q-
Ichip2 
CASE CON CASE CON CASE CON CASE CON CASE CON CASE CON CASE CON 
HLA-B*5501 KIR2DS2 5.97x10
−5
 0.61 0.19 2019 12650 0.034 0.034 0.52 0.51 21 240 923 5994 1028 6230 47 186 
HLA-B*5501 KIR2DL2 0.00013 0.6 0.21 1983 12563 0.034 0.033 0.511 0.508 21 233 922 5993 993 6151 47 186 
HLA-
DQB1*0601 
KIR2DL3 0.0032 0.14 0.17 2062 12975 0.012 0.0097 0.905 0.905 17 118 188 1215 1850 11634 7 8 
HLA-
DRB1*1502 
KIR2DL3 0.0042 0.2 0.18 1920 12349 0.012 0.0104 0.908 0.908 16 119 170 1133 1727 11088 7 9 
HLA-B*3801 KIR2DS4TOTAL 0.0047 0.16 0.19 2056 12800 0.025 0.023 0.956 0.955 46 287 85 575 1919 11931 6 7 
HLA-B*3801 KIR3DL1ex4 0.0047 0.16 0.16 2055 12807 0.025 0.023 0.956 0.954 46 287 85 576 1918 11937 6 7 
HLA-B*3801  KIR3DL1ex9 0.0048 0.16 0.19 2053 12805 0.026 0.023 0.956 0.954 47 290 85 575 1915 11933 6 7 
HLA-
DQA1*0103 
KIR2DL3 0.0078 0.57 0.5 2078 13106 0.084 0.120 0.905 0.906 147 1422 170 1086 1733 10453 28 145 
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Number of individuals with cervical neoplasia cases and healthy control present KIR-HLA combinations are shown. Combination P-values were calculated 
from meta-analysis between Omni-Ichip1 and 660Q-Ichip2 datasets. P-values of each dataset were calculated by using R code glm model with principal 
components 1-4. CON: controls; OR: Odds Ratio. 
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FIGURE LEGENDS 
Figure 1. KIR proteins are classified by the number of extracellular immunoglobulin domains (2D or 
3D) and by whether they have a long (L) or short (S) cytoplasmic domain. Inhibitory KIRs and 
KIR2DL4 have immunoreceptor tyrosine-based inhibitory motifs (ITIM) in their cytoplasmic domains. 
Activating KIRs possess a basic amino acid in the transmembrane domain, which allows interactions 
with the accessory molecule, DAP-12, delivering activating signals through its immunoreceptor 
tyrosine-based activating (ITAM) motif. The ligands for several KIR proteins are subsets of HLA class I 
proteins. KIR2DL4 has a charged amino acid and ITIM motifs, and it interacts with the accessory 
protein, FcεRI-γ, which sends an activating signal via its ITAM similar to DAP-12. Note that HLA-Bw6 
alleles are not known to be KIR ligands.  
 
Figure 2. HLA and KIR gene imputation and association tests were performed using genotype data 
from 2,143 cervical neoplasia cases and 13,858 healthy controls of European descent. 791 
individuals were genotyped using Illumina OmniExpress Beadchip (“Omni”) and 1,352 individuals 
using Illumina Human660-Quad BeadChip (“660Q”). All 13,428 controls were genotyped using 
Illumina Immunochip BeadChip. To avoid imputation bias caused by different number of key SNPs 
between Omni and 660Q, these two groups of cases were imputed separately, and compared with 
two control groups – Immunochip control group 1 (Ichip1, n=6,703) and group2 (Ichip2, n=6,725) – 
obtained by randomly dividing the controls. 77 key SNPs for Omni cases and Ichip1 and 66 key SNPs 
for 660Q cases and Ichip2 were re-clustered and used for imputation. Case-control analyses were 
conducted separately, followed by meta-analysis. 
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Figure 3. Pairwise linkage disequilibrium (r2) plot of HLA alleles associated with cervical neoplasia. 
HLA alleles are clustered according to their pairwise linkage disequilibrium on both the x– and y-
axes. On the y-axis, alleles are labelled as to whether they are risk or protective alleles in the overall 
cervical neoplasia dataset, and on the x-axis according to whether they are HLA Class I or II alleles. 
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Figure 1. 
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Figure 2. 
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Figure 3. 
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